A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.

Purpose: The first-in-human phase 1 trial examined the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetic profile, and antitumor activity of TLC388, a novel camptothecin with a unique lactone ring modification, in patients with advanced solid tumors.

Experimental Design: TLC388 was administered intravenously to patients with metastatic chemotherapy refractory solid tumors on days 1, 8, and 15 of a 28-day cycle. Patients underwent tumor assessments every other cycle.

Interactions of Pluronics with phospholipid monolayers at the air-water interface.

Pluronics are triblock copolymers which are extensively applied excipients shown to interact with cell membranes. The aim of our study was to apply monolayer techniques and epifluorescence microscopy to investigate the interaction behavior between selected Pluronics and phospholipid monolayers which serve as a model of cell membranes. The results showed that Pluronic L61 with hydrophobic proportions much larger than those of F68 demonstrated condensed film-like surface behavior while F68 exhibited more expanded behavior.